According to U. S. News Dr., Columbia University Asa Abeliovich have finally solved the mystery of the molecule is a carrier of cholesterol (APOE4). As you know, this molecule increases the risk of developing Alzheimer's disease, but not one of the scientists could not explain this pattern.
Statement of speakers Abeliovich based on research, which involved two groups. In the first group consisted of 100 people with APOE4, the second group of control. The results were based on the performance of participants who have not observed the bright signs of the disease. Thus, managed to establish why, in spite of the presence of the molecule is a carrier of cholesterol in the body, the likelihood of dementia is increased by 3-10 times, but with all that memory problems are not all the patients.
After a more detailed study of 215 genes were observed change in expression. Of the total number of gene only 20 are key and regulate intracellular processes. They affect the development of the disease process, but of the 20 allocated 2 controller, which met in the cage, it is SV2A and RNF219. These controllers vary depending on the type of apolipoprotein E (APOE).
Thus, it is apolipoprotein E is a direct carrier of cholesterol and in which there are three main types of APOE2, APOE3 and APOE4. The last type is the most dangerous and indicative of Alzheimer's disease. APOE2 is the initial stage where the risk is minimal, APOE3 - middle stage, when you should think about the consequences.
The cell gets only complete combination APOE + receptor + precursor of beta-amyloid.
Genes SV2A and RFN219 affect APOE4, the result of the changes. The result of all this is the accumulation of beta-amyloid protein, which affects neurodegenerative diseases.
However, scientists immediately hastened to cheer patients levetiracetam has the property of blocking SV2A, resulting even in the presence of APOE4, the cells continue to process the precursor protein in their normal mode. This fact gives hope for a cure for Alzheimer's disease.